Onkologie, Hämatologie - Daten und Informationen
SitemapSitemap  


12 Gerinnungsstörungen und Thrombosen: Literatur

Autor/en: A. Matzdorff, M. Dicato
Letzte Änderung: 25.01.2006
  • Aschwanden M, Labs KH, Engel H, Schwob A, Jeanneret C, Mueller-Brand J, Jaeger KA.
    Acute deep vein thrombosis: early mobilization does not increase the frequency of pulmonary embolism.
    Thromb Haemost 2001;85:42-46. PM:11204585
    [Medline]


  • Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer TH, Fey MF.
    Coagulation markers predict survival in cancer patients.
    Thromb Haemost 2002;88:745-749. PM:12428088
    [Medline]


  • Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A, Dietrich-Neto F for the ENOXACAN II investigators.
    Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    N Engl J Med 2002;346:975-980. PM:11919306
    [Medline]


  • Breitkreutz I, Benner A, Moehler T, Glasmacher A, Schmidt-Wolf I, Martin H, Hoelzer M, Salwender H, Ho AD, Goldschmidt H.
    Initial therapy with thalidomide in multiple myeloma: no increase of adverse events compared to standard therapy.
    Onkologie 2003;26:127.


  • Caine GJ, Stonelake PS, Rea D, Lip GYH.
    Coagulopathic complications in breast cancer.
    Cancer 2003;998:1578-1586. PM:14534872
    [Medline]


  • Carr KM, Rabinowitz I.
    Physician compliance with warfarin prophylaxis for central venous catheters in patients with solid tumors.
    J Clin Oncol 2000;18:3665-3667. PM:11054439
    [Medline]


  • Dempfle CE.
    Coagulopathy of sepsis.
    Thromb Haemost 2004;91:213-224. PM:1496114
    [Medline]


  • Dicato MA, Schroell-Metzger B, Bosseler M, Larcher ME, Duhem C, Heintz D, Gerchem G, Ries F.
    The mutations V Leiden, MTHFR and PT do not need to be determined in cancer patients with venous thromboembolic disorders unless they have a personal or family history of thrombophilia.
    Blood 2003;102:118.


  • Edwards RL, Silver J, Rickles FR.
    Human tumor procoagulants: registry of the subcommittee on haemostasis and malignancy of the scientific and standardization committee, International Society on Thrombosis and Haemostasis.
    Thromb Haemost 1993;69:205-213. PM:8456435
    [Medline]


  • ENOXACAN Study Group.
    Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: a double-blind randomized multicentre trial with venographic assessment.
    Br J Surg 1997;84:1099-1103. PM:9278651
    [Medline]


  • Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson FA, Wheeler HB.
    Prevention of venous thromboembolism.
    Chest 2001;119:132-175. PM:11157647
    [Medline]


  • Goldschmidt N, Linetsky E, Shalom E, Varon D, Siegal T.
    High incidence of thromboembolism in patients with central nervous system lymphoma.
    Cancer 2003;98:1239-1242. PM:12973848
    [Medline]


  • Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM.
    Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis.
    Ann Intern Med 1999;130:800-809. PM:10366369
    [Medline]


  • Green D, Hull RD, Brant R, Pineo GF.
    Lower mortality in cancer patients treated with low-molecular-weight versus standard heparin.
    Lancet 1992;339:1476. PM:1351142
    [Medline]


  • Hettiarachchi RJK, Smorenburg SM, Ginsberg J, Levine M, Prins MH, Büller HR.
    Do heparins do more than just treat thrombosis? The influence of heparins on cancer spread.
    Thromb Haemost 1999;82:947-952. PM:10605808
    [Medline]


  • Hull RD, Pineo GF, Mah AF, Brant RF, for the Lite Study Investigators.
    A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium.
    Blood 2002;100:148.


  • Hyers TM, Agnelli G, Hull RD, Morris TA, Samama M, Tapson V, Weg JG.
    Antithrombotic therapy for venous thromboemoblic disease.
    Chest 2001;119:176-193. PM:11157648
    [Medline]


  • Kakkar AK, Kadziola Z, Williamson RCN, Levine MN, Low V, Lemoine NR, on Behalf of the Fragmin Advanced Malignancy Outcome Study (FAMOUS) Investigators.
    Low molecular weight heparin therapy and survival in advanced cancer.
    J Clin Oncol 2004;22:1944-1948. PM:15143088
    [Medline]


  • Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T, European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators.
    Efficacy and safety of low-dose aspirin in polycythemia vera.
    N Engl J Med 2004;350:114-124. PM:14711910
    [Medline]


  • Lee AYY, Levine MN, Baker RI, Bowden C, Kakkar AK, Prins M, Rickles FR, Julian JA, Haley S, Kovacs MJ, Gent M for the Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators.
    Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    N Engl J Med 2003;349:146-153. PM:12853587
    [Medline]


  • Levine MN.
    Prevention of thrombotic disorders in cancer patients undergoing chemotherapy.
    Thromb Haemost 1997;78:133-136. PM:9198142
    [Medline]


  • Look M, van Putten W, Duffy M, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Ferno M, Eppenberger-Castori S, Fred Sweep CG, Ulm K, Peyrat JP, Martin PM, Magdelenat H, Brunner N, Duggan C, Lisboa BW, Bendah PO, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder M, Manders P, Edward Fiets W, Blankenstein M, Broet P, Romain S, Daxenbichler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex L, Klijn J, O'Higgins N, Eppenberger U, Janicke F, Schmitt M, Foekens J.
    Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients.
    Thromb Haemost 2003;91:538-548. PM:12958624
    [Medline]


  • Lutz L, Haas S, Hach-Wunderle V, Betzl G, Jarmatz H.
    Venöse Thromboembolie in der Inneren Medizin. Risikoeinschätzung und medikamentöse Prophylaxe.
    Med Welt 2002;53:231-234. PM:


  • Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cotta P, Farge D.
    Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer.
    Arch Intern Med 2002;162:1729-1735. PM:12153376
    [Medline]


  • Monreal M, Alastrue A, Rull M, Mira X, Muxart J, Rosell R, Abad A.
    Upper extremity deep venous thrombosis in cancer patients with venous access devices.
    Thromb Haemost 1996;75:251-253. PM:8815570
    [Medline]


  • Nowak-Göttl U, Wermes C, Junker R, Koch HG, Schobess R, Fleischhack G, Schwabe D, Ehrenforth S.
    Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors.
    Blood 1999;93:1595-1599. PM:10029588
    [Medline]


  • Oger E, Bressollette L, Nonent M, Lacut K, Guias B, Couturaud F, Leroyer C, Mottier D.
    High prevalence of asymptomatic deep vein thrombosis on admission in a medical unit among elderly patients.
    Thromb Haemost 2002;88:592-597. PM:12362229
    [Medline]


  • Ornstein LD, Zacharski LR.
    The use of heparin for treating human malignancies.
    Haemostasis 1999;29:48-60. PM:10629404
    [Medline]


  • Otten HMMB, Prins MH.
    Venous thromboembolism and occult malignancy.
    Thromb Research 2001;102:187-194. PM:11516452
    [Medline]


  • Prandoni P, Lensing AWA, Piccioli A, Bernardi E, Simioni P, Girolami B, Marchiori A, Sabbioni P, Prins MH, Noventa F, Girolami A.
    Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
    Blood 2002;100:3484-3488. PM:12393647
    [Medline]


  • Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Elias AD, Antin JH, Soiffer R, Spitzer T, Avigan D, Bearman SI, Martin PL, Kurtzberg J, Vredenburgh H, Chen AR, Arai S, Vogelsang G, McDonald GB, Guinan EC.
    Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome.
    Blood 2002;100:4337-4343. PM:12393437
    [Medline]


  • Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G.
    Disseminated intravascular coagulation in solid tumors: clinical and pathologic study.
    Thromb Haemost 2001;86:828-833. PM:11583315
    [Medline]


  • Sallah S, Wan JY, Nguyen NP.
    Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.
    Thromb Haemost 2002;87:575-579. PM:12008937
    [Medline]


  • Samama MM, Cohen AT, Darmon J-Y, Desjardins L, Eldor A, Janbon C, Leizorovicz A, Nguyen H, Olsson C-G, Turpie AG, Weisslinger N, the Prophylaxis in Medical Patients with Enoxaparin Study Group.
    A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients.
    N Engl J Med 1999;341:793-800. PM:10477777
    [Medline]


  • Santos AB, Llamas P, Román A, Prieto E, De Ona R, De Velasco JF, Thomas JF.
    Evaluation of thrombophilic states in myeloma patients receiving thalidomide: a reasonable doubt.
    Br J Haematol 2003;122:159-160. PM:12823358
    [Medline]


  • Schulman S, Lindmarker P, for the duration of anticoagulation (DURAC) trial.
    Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism.
    N Engl J Med 2000;342:1953-1958. PM:10874063
    [Medline]


  • Smorenburg SM, van Noorden CJF.
    The complex effects of heparins on cancer progression and metastasis in experimental studies.
    Pharmacol Rev 2001;53:93-105. PM:11171940
    [Medline]


  • Van Rooden CJ, Monraats PS, Kettenis MJ, Rosendaal FR, Huisman V.
    Low physician compliance of prescribing anticoagulants prophylaxis in patients with solid tumor or hematological malignancies and central vein catheters.
    J Thromb Hemost 2003;1:1842-1843. PM:12911604
    [Medline]


  • Von Tempelhoff GF, Harenberg J, Niemann F, Hommer L, Kirkpatrick CJ, Heilmann L.
    Effect of low molecular weight heparin (certoparin) versus unfractionated heparin on cancer survival following breast and pelvic cancer surgery.
    Int J Oncol 2000;16:815-824. PM:10717252
    [Medline]


  • Warrell RP, de The H, Wang ZY, Degos L.
    Acute promyelocytic leukemia.
    N Engl J Med 1993;329:177-189. PM:8515790
    [Medline]


  • Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ.
    Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis.
    N Engl J Med 2003;349:1227-1235. PM:14507948
    [Medline]


  • Zacharski LR, Ornstein DL, Mamourian AC.
    Low-molecular-weight heparin and cancer.
    Semin Thromb Hemost 2000;26:69-77. PM:11011810
    [Medline]


Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag"
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
[Mehr]